Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at ACC24

News | Cardiovascular Clinical Studies

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be Presented at ACC.24

March 26, 2024 — Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL ...

March 26, 2024

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

News | ACC

Bristol Myers Squibb to Present Data on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

March 26, 2024

Here is a look at the education and special events planned for the ACC24 73rd Annual Scientific Session & Expo, April 6-8 in Atlanta

Feature | ACC | By Melinda Taschetta-Millane

American College of Cardiology (ACC24) Show Preview: Advancing Cardiovascular Care for All

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

March 25, 2024

Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption (IDE) clinical trial.

News | Cardiovascular Clinical Studies

Abbott Announces First Procedures in ENVISION Trial of Navitor TAVI System to Treat Patients With Severe Aortic Stenosis

March 25, 2024 — Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption ...

March 25, 2024

A bioelectronic mesh, studded with graphene sensors (red), can measure the electrical signal and movement of cardiac tissue (purple and green) at the same time.

News | Heart Failure

UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive Heart Monitoring

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the Ma ...

March 25, 2024

A clinical trial at Cedars-Sinai is testing the safety and efficacy of a device aimed at managing treatment-resistant hypertension. Photo by Getty.

News | Hypertension

Cedars-Sinai Experts Studying Device for Controlling Treatment-Resistant Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

March 18, 2024

Visual Thrombus Assessment as presented by Dr. William Gray at the Cardiovascular Research Technologies (CRT) 2024 conference.

News | Left Atrial Appendage (LAA) Occluders

Conformal Medical's CLAAS System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

March 18, 2024 — Conformal Medical, Inc. announced that the CLAAS System was featured in a podium presentation at the Ca ...

March 18, 2024

First-of-its-kind trial in US shows drug-coated balloons are a superior treatment option for patients undergoing coronary angioplasty

News | Cardiovascular Clinical Studies

BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

March 13, 2024

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

News | Heart Failure

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

March 13, 2024

Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.

News | Cardiovascular Clinical Studies

Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

March 13, 2024

The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease

News | FDA

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...

March 08, 2024

Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial

News | FDA

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

March 6, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

March 06, 2024

Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation for their ECGvision-TTR Technology

News | FDA

Ensight-AI Awarded FDA’s Breakthrough Device Designation for Its ECGVision-TTR Technology for Early Detection of ATTR-Cardiomyopathy

March 6, 2024 — Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of ...

March 06, 2024

Bodyport Inc., a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

News | Cardiovascular Clinical Studies

Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) Conference

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

March 06, 2024

Lantheus announced that the U.S. Food and Drug Administration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly.

News | FDA

Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

March 6, 2024 — Lantheus Holdings, Inc. (Lantheus), a radiopharmaceutical company, has announced that the U.S. Food and ...

March 06, 2024